ClinicalTrials.gg
RecruitingNCT07737899PrimPalUpdated Nov 9, 2026

Primary Palliative Care - a Feasibility Cluster Trial

An interventional study of Primary Palliative Care Complex Intervention (PrimPal) in Palliative Care, Primary Palliative Care and Advanced Cancer, sponsored by University of Coimbra. Recruiting at 2 sites in Portugal. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by University of Coimbra · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 9, 2026Now RecruitingSite recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies in Pulmonary Disease, Chronic Obstructive with a site in Portugal — 14 open to participants now, 16 under way, 3 of them phase 3. Pulmonary Disease, Chronic Obstructive · Portugal.

Planned enrollment
46th of 49
30 · median 258
Started
2026
with 3 others
No phase
23 of 54
9 open now
Primary completion
2027-02
later than 10 of 15 live
Registered
52nd of 54
by date

Among the 54 studies in Pulmonary Disease, Chronic Obstructive with a site in Portugal, this one is the 46th largest by planned enrollment of the 49 interventional ones that give a count, is one of 4 that started in 2026, is one of 23 with no phase, reaches primary completion later than 10 of the 15 other live ones, and was the 52nd registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

14 of the 54 studies in Pulmonary Disease, Chronic Obstructive with a site in Portugal are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Pulmonary Disease, Chronic Obstructive with a site in Portugal, or all of them as a file.
02

Study summary

This feasibility cluster-controlled randomized trial (RCT) evaluates a complex intervention for the delivery of primary palliative care in Family Health Units (FHUs). The intervention consists of training General Practitioners (GPs) in palliative care through a 30 hour e-learning program and implementing a structured consultation model (4 consultations over 12 weeks) for adult patients with advanced chronic illness. One FHU will receive the intervention and one FHU will follow usual care. The primary goal is to assess feasibility metrics (GP adherence, patient recruitment rate, and patient retention rate), which will inform the design of a subsequent full-scale cluster RCT.

Read the detailed description

Background: Demographic ageing and the rising burden of chronic disease have dramatically increased the need for palliative care. Most patients with palliative care needs are cared for in primary health care (PHC) settings, yet GPs often lack training and systematic tools to identify and manage these patients. The Principal Investigator developed a complex intervention combining GP training and a new consultation model during doctoral research, demonstrating promising results (reduction in physical and psychological symptoms) in a before-after study (published in Palliative Medicine, DOI: 10.1177/02692163231219682). The present feasibility trial is the next methodological step before undertaking a full-scale cluster RCT.

Design: Feasibility cluster-controlled RCT with an embedded qualitative component (mixed-methods). Randomisation occurs at the cluster (FHU) level. Two FHUs from ULS Coimbra (central Portugal) will be recruited: one allocated to the intervention arm and one to the control (usual care) arm.

Intervention: GPs in the intervention FHU will complete a 30hour e-learning training programme covering palliative care communication, symptom management, and patient assessment/control. After training, each GP will apply the new structured consultation model to recruited patients over 12 weeks (4 consultations). The model is grounded in the 4th edition of the National Consensus Project's Clinical Practice Guidelines for Quality Palliative Care and WONCA's core competencies for GPs in palliative care.

Control: GPs in the control FHU will follow usual care without any specific palliative care training or structured consultation model.

Participants: Adult patients (≥18 years) on the list of recruited GPs with a diagnosis of: advanced-stage neoplasm (metastatic cancer), COPD GOLD III/IV, Congestive Heart Failure NYHA III/IV, or Chronic Kidney Disease stage IV/V.

Feasibility outcomes: GP implementation rate (primary), patient recruitment rate, and patient retention rate will be assessed at baseline (T0), week 6 (T1), and week 12 (T2). Qualitative data will be collected through interviews with GPs and patients to explore perceived barriers and benefits of the intervention.

Significance: Results will be used to refine the intervention and study procedures, and to power a future definitive cluster RCT.

03

Conditions studied

  • Palliative Care
  • Primary Palliative Care
  • Advanced Cancer
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Congestive Heart Failure Chronic
  • Chronic Kidney Disease (Stages 4 and 5)

Keywords

  • Palliative care
  • Primary Palliative Care
  • General practice
  • Family medicine
  • Feasibility study
  • Cluster randomized controlled trial
  • Complex intervention
  • Chronic disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years or older.
  • Enrolled as a patient on the list of a recruited General Practitioner in one of the participating Family Health Units.
  • Diagnosed with one or more of the following advanced chronic conditions:
  • Advanced-stage neoplasm (/stage IV cancer);
  • (COPD) - GOLD classification III or IV;
  • Congestive Heart Failure (CHF) - (NYHA) functional classification III or IV;
  • Chronic Kidney Disease (CKD) - stage IV or V.

Exclusion criteria

Exclusion Criteria:

  • Refusal to provide or to participate in the study at any point.
  • Disease severity requiring urgent medical intervention (acute crisis/emergency care need at time of recruitment).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Primary Palliative Care Consultation

    General Practitioners in the intervention FHU complete a 30hour e-learning training programme in palliative care and apply a new structured consultation model over 12 weeks (4 consultations) with recruited patients.

    Other: Primary Palliative Care Complex Intervention (PrimPal)

  • No intervention
    Control (Usual Care)

    GPs in the control FHU deliver usual palliative care without specific training or structured consultation model.

Interventions

  • OtherPrimary Palliative Care Complex Intervention (PrimPal)

    1. GPs will receive an e-learning palliative care training programme with a 30-h load, including topics such as the role of communication, the main problems and symptoms of patients with palliative care needs and how to assess and control them. Additionally, the programme covered how to apply the newly developed medical consultation model and how to use the Integrated Palliative Care Outcome Scale (IPOS) patient version 2. Primary palliative care consultation model divided into five areas (1) summarizing clinical information, (2) objective symptoms' management, (3) assessment and coding of chronic diseases and symptoms, (4) planning clinical approach and (5) addressing other problems/concerns - 4 consultations over 12 weeks.

06

What researchers measure

Primary outcomes

  1. GP Feasibility Rate (Implementation Rate)

    Percentage of GPs in the intervention arm who successfully implement the new consultation model with their recruited patients (excluding failures due to reasons unrelated to the physician, e.g., patient death or withdrawal). Feasibility is considered demonstrated if ≥70% of GPs complete the model with at least 80% of their recruited patients.

    Time frame: 12 weeks (from start of intervention to end of consultation cycle - Week 12 / T2)

Secondary outcomes

  1. Patient Recruitment Rate

    Percentage of contacted eligible patients who agree to participate in the study.

    Time frame: Baseline (T0) - during recruitment period

  2. Patient Retention Rate

    Percentage of enrolled patients who complete all 4 consultations and remain in the study until week 12.

    Time frame: Week 12 (T2)

  3. Perceived Barriers to Implementation

    Qualitative exploration of obstacles experienced by GPs and patients in the implementation of the intervention, assessed via semi-structured interviews

    Time frame: Week 12 (T2) - end of intervention

  4. Perceived Benefits of the Intervention

    Qualitative exploration of the benefits perceived by GPs and patients from the intervention, assessed via semi-structured interviews.

    Time frame: Week 12 (T2) - end of intervention

07

Study locations

2 of 2 sites recruiting
  • Family Health Unit 1 - ULS Coimbra (Intervention)
    Coimbra, Portugal
    Recruiting
  • Family Health Unit 2 - ULS Coimbra (Control)
    Coimbra, Portugal
    Enrolling by invitation
08

References and documents

Publications

  • Seica Cardoso C, Prazeres F, Oliveiros B, Nunes C, Simoes P, Aires C, Rita P, Penetra J, Lopes P, Alcobia S, Baptista S, Venancio C, Gomes B. Feasibility and effectiveness of a two-tiered intervention involving training and a new consultation model for patients with palliative care needs in primary care: A before-after study. Palliat Med. 2024 Sep;38(8):842-852. doi: 10.1177/02692163231219682. Epub 2024 Jan 16. PubMed 38226491 ↗
  • Seica Cardoso C, Prazeres F, Nunes C, Simoes P, Aires C, Rita P, Penetra J, Lopes P, Alcobia S, Gomes B. Impact of a complex intervention in primary care for patients with palliative care needs in their healthcare utilization: a before-after study. Prim Health Care Res Dev. 2026 Jan 30;27:e15. doi: 10.1017/S1463423625100777. PubMed 41612825 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Feb 2027, 4 months after the start.

Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 4 months is below that.

Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2026
First posted
Jul 30, 2026
StartActual
Oct 1, 2026
Primary completionEst.
Feb 28, 2027
CompletionEst.
Aug 31, 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 9, 2026
Sites
2 sites changed recruiting status (1 now recruiting, 1 now enrolling by invitation)
Show 2 sites
  • Family Health Unit 1 - ULS Coimbra (Intervention) · Coimbra, Portugalno status→Recruiting
  • Family Health Unit 2 - ULS Coimbra (Control) · Coimbra, Portugalno status→Enrolling by invitation
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Not yet recruiting→Recruiting
    2 sites changed recruiting status (1 now recruiting, 1 now enrolling by invitation)
    Show 2 sites
    • Family Health Unit 1 - ULS Coimbra (Intervention) · Coimbra, Portugalno status→Recruiting
    • Family Health Unit 2 - ULS Coimbra (Control) · Coimbra, Portugalno status→Enrolling by invitation
    + 2 other changes: date precision and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07737899
Lead sponsor
University of Coimbra
Collaborators
Unidade Local de Saúde de Coimbra, EPE
Responsible party
Carlos Seiça Cardoso (Principal Investigator, University of Coimbra) — Principal investigator
First posted
Jul 30, 2026
Start date
Oct 1, 2026
Primary completion
Feb 28, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Nov 9, 2026

Study contacts

Carlos S Cardoso, PhD
Contact
carlosseicacardoso@uc.pt
00351 239 857 700

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion